Targeted Therapy of Glioma: Current Developments in Targeted Drug Delivery Systems
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 20
Special Issue Editor
Special Issue Information
Dear Colleagues,
Despite many years of efforts, gliblastoma multiforme remains one of the most difficult types of cancer to treat. Current therapies remain unsatisfactory, due in part to the difficulty of drug delivery to the central nervous system across the blood–brain barrier (BBB) and the lack of selective action. One rational solution is the use of targeted therapy, which not only selectively destroys glioma cells but also allows them to cross the BBB. The aim of this Special Issue, entitled "Targeted Therapy of Glioma: Current Developments in Targeted Drug Delivery Systems", is to present the latest solutions for targeting therapeutic agents to glioma cells. This Special Issue welcomes submissions of original research articles, review papers, case studies, and clinical trials concerning new assessment methods, drugs, and targeting factors that can increase the effectiveness of glioma therapy and extend the lifespan and quality of life of patients.
Prof. Dr. Łukasz Uram
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma multiforme therapy
- targeted glioma therapy
- in vivo and in vitro studies
- blood–brain barrier crossing
- repurposing drugs
- nanoparticles as targeting factors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
